250 results on '"Miglioresi L"'
Search Results
52. 484 IMPACT OF LIVER FIBROSIS IN DEVELOPMENT OF HEPATOCELLULAR CARCINOMA IN GENOTYPE 1 CHRONIC HEPATITIS C PATIENTS TREATED WITH ANTIVIRAL THERAPY: LONG TERM FOLLOW UP STUDY
53. 139 AN UNFAVORABLE INTERACTION BETWEEN DONOR AGE AND LATENT RECIPIENT CYTOMEGALOVIRUS (CMV) INFECTION AFTER LIVER TRANSPLANTATION (LT): INSIGHTS FROM THE LIVER MATCH STUDY
54. P.18.2 LONG-TERM MAINTENANCE OF SVR IN DIFFICULT-TO-TREAT HCV GENOTYPES IN LIVER TRANSPLANT RECIPIENTS WITH HCV RECURRENCE
55. T-45 Features of patients with extrahepatic metastasis of hepatocellular carcinoma and clinical impact on survival: experience of a single Italian center
56. P.04.4 SVR TO ANTIVIRAL TREATMENT FOR POST-OLT RECURRENT HCV HEPATITIS CAN BE IMPROVED BY THE USE OF GROWTH FACTORS
57. P.03.6 IS THE PRIMARY IMMUNOSUPPRESSIVE DRUG (CYCLOSPORIN A OR TACROLIMUS) PLAYING A ROLE ON THE RESPONSE TO ANTIVIRAL TREATMENT FOR POST-TRANSPLANT HCV RECURRENCE?
58. P.04.9 THE PRESENCE OF DIABETES REDUCES SVR AFTER ANTIVIRAL THERAPY FOR POST-TRANSPLANT HCV RECURRENCE
59. F-46 Graft survival is worse in HCV positive females transplanted with male donor grafts
60. 563 ACUTE AND CHRONIC REJECTION DURING INTERFERON THERAPY IN HCV RECURRENT TRANSPLANT PATIENTS: RESULTS FORM THE AISF-RECOLT-C GROUP
61. 523 PROTRACTED ANTIVIRAL TREATMENT BEYOND CONVENTIONAL TIME LIMITS IMPROVES SURVIVAL IN NON-RESPONDERS TO INTERFERON+RIBAVIRIN ADMINISTERED FOR HCV RECURRENCE AFTER LIVER TRANSPLANTATION
62. P.1.54: TREATMENT OF THE “UNCOMMON” HCV GENOTYPE 4 INFECTION RECURRENCE AFTER LIVER TRANSPLANTATION. AN “AISF RECOLT-C” STUDY
63. P.1.3: ACUTE AND CHRONIC REJECTION DURING INTERFERON THERAPY IN HCV RECURRENT LIVER TRANSPLANT PATIENTS: RESULTS FROM THE AISF-RECOLT-C GROUP
64. 578 IS THE PRIMARY IMMUNOSUPPRESSIVE DRUG (CYCLOSPORIN A OR TACROLIMUS) PLAYING A ROLE ON THE RESPONSE TO ANTIVIRAL TREATMENT FOR POST-TRANSPLANT HCV RECURRENCE?
65. 561 BEST MATCHING FOR HCV GENOTYPE 1 LIVER TRANSPLANT RECIPIENTS IS PREDICTED BY HCV1-STAR. A STUDY FROM AISF RECOLT-C DATABASE
66. P.1.7: A SVR TO POST-LT ANTIVIRAL TREATMENT IMPROVES LONG-TERM SURVIVAL IN PATIENTS WITH GENOTYPE 1 HCV RECURRENCE: AN “AISF RECOLT-C” GROUP STUDY
67. P.1.2: THE PERSISTENCE OF HCV REPLICATION IS ASSOCIATED WITH AN INCREASED MORTALITY RATE IN HCV RECURRENT TRANSPLANT PATIENTS: RESULTS FROM THE AISF-RECOLT-C GROUP
68. PC.1.4: THE BEST MATCHING FOR HCV GENOTYPE 1 LIVER TRANSPLANT RECIPIENTS IS PREDICTED BY HCV1-STAR. A STUDY FROM AISF RECOLT-C DATABASE
69. 579 THE PRESENCE OF DIABETES REDUCES SVR AFTER ANTIVIRAL THERAPY FOR POST-TRANSPLANT HCV RECURRENCE
70. 427 TREATMENT OF HEPATITIS C RECURRENCE AFTER LIVER TRANSPLANTATION: GENDER ISSUE ON THERAPY OUTCOME
71. 464 TREATMENT OF THE “UNCOMMON” HCV GENOTYPE 4 INFECTION RECURRENCE AFTER LIVER TRANSPLANTATION. AN ITALIAN MULTICENTRIC EXPERIENCE
72. P.1.5: POOR ADHERENCE TO PEGYLATED INTERFERON AND RIBAVIRIN IS A MAJOR CONCERN IN THE TREATMENT OF RECURRENT HEPATITIS C AFTER LIVER TRANSPLANTATION: EVIDENCE FROM THE AISF RECOLT-C STUDY GROUP
73. 532 POOR ADHERENCE TO PEGYLATED-INTERFERON AND RIBAVIRIN IS A MAJOR CONCERN IN THE TREATMENT OF RECURRENT HEPATITIS C AFTER LIVER TRANSPLANTATION: EVIDENCE FROM THE RECOLT-C GROUP
74. T-44 Impact of antiviral therapy on fibrosis progression due to HCV recurrence after liver transplantation: Results from the AISF RECOLT-C study group
75. OC-7 A SVR to post-LT antiviral treatment improves long-term survival in patients with genotype 1 HCV recurrence: An “AISF RECOLT-C” Group Study
76. F-39 Is the primary immunosuppressive drug playing a role on the response to antiviral treatment for post-transplant HCV recurrence?
77. T-43 Treatment of the “uncommon” HCV genotype 4 infection recurrence after liver transplantation. Data from AISF RECOLT-C group
78. T-24 Donor-related characteristics as predictors of sustained virologic response to antiviral therapy in recurrent hepatitis C after liver transplantation
79. F-48 HCV relapses occur within 3 months after treatment in liver transplanted patients receiving pegylated IFN and ribavirin
80. F-31 The persistence of HCV replication is associated with an increased mortality rate in HCV recurrent transplant patients: Results from the AISF-RECOLT-C group
81. T-23 Poor adherence to pegylated interferon and ribavirin is a major concern in the treatment of hepatitis C after liver transplantation: Evidence from the AISF RECOLT-C study group
82. F-10 Acute and chronic rejection during interferon therapy in HCV recurrent transplant patients: Results from the AISF-RECOLT-C group
83. OC-24 The best matching for HCV genotype 1 liver transplant recipients is predicted by HCV1-STAR. A study from “AISF RECOLT-C” database
84. DE NOVO TUMORS AFTER LIVER TRANSPLANTATION: RESULTS FROM A MULTICENTRIC STUDY, ITALY 1990–2008.
85. T.N.49 FIBROSIS PROGRESSION IN NON RESPONDERS TO ANTIVIRAL TREATMENT (AT) FOR HCV RECURRENCE FOLLOWING LIVER TRANSPLANTATION (LT)
86. The controversial role of lamivudine prophylaxis in occult HBV carriers treated with chemo-immune therapy
87. Consensus interferon versus interferon-α 2b plus ribavirin in patients with relapsing HCV infection
88. 7 OP COX-2 inhibition can change portal and splenic blood flow
89. Cox-2 inhibition can change portal and splenic blood flow
90. Multiple viral infections in a group of intravenous drug users: hepatitis B virus exposure is the risk factor
91. What Kind of Hepatitis?
92. Increased sustained response of HCV relapsing patients with consensus interferon (alfacon) vs recombinant alpha-interferon-2b plus ribavirin (IFN+RB)
93. Elevated Alanine Aminotransferase in Blood Donors: Role of Different Factors and Multiple Viral Infections
94. Association of circulating CD8+ lymphocytes to a spontaneous and interferon-α induced clearance of HCV.
95. Association of circulating CD8 + lymphocytes to a spontaneous and interferon-α induced clearance of HCV
96. Combined treatment of HCV infection: is there a need for meta-analysis?
97. Indications and outcome of liver transplantation poit center experience | Indicazioni attuali nel trapianto di fegato esperienza del centro trapianti del poit
98. DE NOVO MALIGNANCIES FOLLOWING LIVER TRANSPLANTATION. RESULTS FROM A MULTICENTRIC STUDY IN ITALY: 1990-2010
99. De Novo Malignancies after Organ Transplantation: Focus on Viral Infections
100. Liver transplantation in HIV patients,Il trapianto di fegato nei pazienti HIV positivi
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.